In vitro drug testing using patient-derived ovarian cancer organoids
In vitro drug testing using ovarian cancer organoids is feasible and correlates well with patient clinical responses. These results may facilitate development of precision chemotherapy and personalized screening for repurposed or new drugs.
Authors
- Lin‐Yu Chen (ORCID: https://orcid.org/0000-0003-4870-3664)
- Shiou‐Fu Lin (ORCID: https://orcid.org/0000-0001-7198-7234)
- Ling-Hui Chu
- Yu‐Chun Weng (ORCID: https://orcid.org/0000-0002-4829-8737)
- Hung‐Cheng Lai (ORCID: https://orcid.org/0000-0001-8048-3943)
- Hui-Chen Wang
- Yu‐Ting Chou (ORCID: https://orcid.org/0000-0001-9274-8603)
- Po‐Hsuan Su (ORCID: https://orcid.org/0000-0003-1114-6382)
- Kuo‐Chang Wen (ORCID: https://orcid.org/0000-0001-6967-8037)
- Phui‐Ly Liew (ORCID: https://orcid.org/0000-0003-2156-5628)
Institutions
- Tri-Service General Hospital (TW)
- National Taipei University of Nursing and Health Science (TW)
- Taipei Medical University-Shuang Ho Hospital (TW)
- Taipei Medical University (TW)
- National Defense Medical Center (TW)
Publication Details
- Journal
- Journal of Ovarian Research
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1186/s13048-024-01520-2
- Citations
- 11
- Primary Topic
- Renal and related cancers
- Type
- article
- Field-Weighted Citation Impact
- 2.57
Funders
- Ministry of Science and Technology, Taiwan
- Taipei Medical University
- Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare